Cancer Research UK and Astellas Pharma announced a two-year collaboration to find new drug targets for pancreatic cancer based on the theory of autophagy. Researchers will first study drug targets for blocking the autophagy pathway in pancreatic cancer cells. Cancer Research UK's commercial arm, Cancer Research Technology, will receive milestone payments and royalties from Astellas for the most promising candidates.

Full Story:
PharmaTimes (U.K.)

Related Summaries